CML patient with positive HBV serology (HBsAg+ or anti-HBc+) — TKI therapy is associated...

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

ID	`RF-CML-INFECTION-SCREENING`
Type	Red flag
Status	reviewed 2026-04-25 \| pending_clinical_signoff
Diseases	`DIS-CML`
Sources	`SRC-ELN-CML-2020` `SRC-NCCN-MPN-2025`

Red Flag Origin

Definition	CML patient with positive HBV serology (HBsAg+ or anti-HBc+) — TKI therapy is associated with HBV reactivation in case reports; mandatory HBV testing pre-TKI + active prophylaxis (entecavir / tenofovir) if HBsAg+, monitoring if anti-HBc+ only
Clinical direction	investigate
Category	infection-screening

Trigger Logic

{
  "any_of": [
    {
      "finding": "hbsag",
      "value": "positive"
    },
    {
      "finding": "anti_hbc_total",
      "value": "positive"
    },
    {
      "finding": "hcv_rna",
      "value": "positive"
    },
    {
      "finding": "hiv_status",
      "value": "positive"
    }
  ],
  "type": "composite"
}

Notes

Direction "investigate" — surfaces a workup-prerequisite annotation. CML TKI-related HBV reactivation is rare but reported (especially with immunosuppression-dose TKI shifts and post-TFR discontinuation). HBV testing recommended before initiating any TKI per ELN 2020 + NCCN. STUB — requires clinical co-lead signoff.

CML patient with positive HBV serology (HBsAg+ or anti-HBc+) — TKI therapy is associated...

Red Flag Origin

Trigger Logic

Notes

Used By

Algorithms

Indications